At Shattuck Labs, we are pioneering a new class of dual function fusion proteins to create novel therapeutics for patients with cancer and autoimmune disease.
Shattuck was founded in 2016 with the goal of building a fully integrated biotechnology company that creates novel therapeutics for the treatment of cancer and autoimmune disease. At the core of that vision was creating a company that brings together leading scientists, drug manufacturers, physicians, and other professionals to challenge conventional thinking and develop transformational medicines that measurably improve the lives of our patients.
One of the truly differentiating aspects of Shattuck has been the novelty of our proprietary Agonist Redirected Checkpoint (ARC) platform technology. Combining a strong technological foundation with deep professional expertise has allowed us to deliver on our broader corporate mission. Demonstrating our sense of urgency, we were able to bring our first compound to the clinic within two years of founding the company.
With over 300 ARC compounds produced to date, Shattuck’s research and discovery engine has yielded enormous results. Our discovery production is a cornerstone of all that we do, and we have invested heavily in understanding the science behind all of our compounds. As a result of the significant investment in our platform, we are able to move compounds from bench to clinic in fewer than 18 months, well ahead of industry-standard timelines.
Today we have two product candidates in global clinical trials, treating patients with a high unmet need in cancer. Our constant pursuit of excellence continues to drive us to build a company at the helm of providing truly breakthrough medicines for patients in need.
Mission & Vision
Our vision is to build incredible medicines off the beaten path, by challenging ourselves to think differently.
We work with a sense of urgency, focused on scientific excellence and thoughtful stewardship of resources, to translate innovative ideas into medicines that improve the lives of patients with serious diseases.